Laurence Klotz, MD, discusses a liquid biopsy urine test that uses microRNA expression profiles to identify clinically significant prostate cancer in patients. He emphasizes the ease and efficiency of the technology, in addition to its high degree of sensitivity and specificity.
Read More
Sigrid V. Carlsson, MD, PhD, MPH, Faina Shtern, MD, and Wendy L. Poage, MHA, three leaders in the urologic field, each with a unique background, discuss the challenges faced and successes accomplished for women working in urology and medicine as a whole. They also share advice for younger women aspiring to enter these fields.
Read More
E. David Crawford, MD, discusses the wide range of clinical possibilities related to prostate cancer imaging with a novel 29 MHz micro-ultrasound technology. He specifically deliberates the possibility of micro-ultrasound to improve screening pathways and focal therapy protocols.
Read More
Laurence Klotz, MD, discusses the limitations of multiparametric MRI (mpMRI) targeted prostate biopsy, especially in the active surveillance setting, and how a novel 29 MHz high resolution micro-ultrasound technology could be an improved alternative. Additionally, he describes his experience with this technology at his institution.
Read More
Daniel P. Petrylak, MD, discusses patient selection for currently-approved immunotherapies for prostate cancer, especially in patients with microsatellite instability. He also emphasizes the importance of utilizing immunotherapy early in the disease course.
Read More